Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Recent scientific advances have yielded promising new treatment options for patients with cancer, but these achievements in translational medicine have been increasingly overshadowed by public controversy because of their cost.1 With the advent of combination immunotherapies whose list prices may exceed $300 000 per year, several drug industry leaders have joined calls for a “more rational” and “sustainable” system of cancer drug pricing.2
Hwang TJ, LaMattina JL. Measuring the Value of New Medications and Implications for Medicare’s Proposed Part B Drug Payment Model. JAMA Oncol. 2016;2(9):1125–1126. doi:10.1001/jamaoncol.2016.2037
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: